Valeant, an Aggressive Buyer of Drug Companies, Acquires Its Way to Mediocrity
Posted on June 20, 2011 at 15:33 PM EDT
Could Valeant be growing up, and in so doing turning into just another boring old drug company? Its numbers suggest that's exactly what's happening: It's acquiring its way to mediocrity.
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here